Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in ...

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at markets.businessinsider.com →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

Erasca has received FDA Fast Track Designation for its oral pan-RAS molecular glue ERAS-0015 aimed at treating metastatic pancreatic adenocarcinoma, following encouraging Phase 1 trial results. The designation is expected to expedite clinical development including planned Phase 3 and pivotal trials for pancreatic and lung cancers.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

The FDA’s fast track for ERAS-0015 opens a quicker path to market for novel pancreatic cancer treatments. You can leverage this as a blueprint to engage regulators early and focus your development on high-impact oncology targets.

◆ Coverage

1 source · 24 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfdafast-trackpancreatic-cancermolecular-glueclinical-trials